Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
55/100
Efforts to use plasma levels of Abeta peptides as AD biomarkers or disease-staging scales have failed.
-
The hippocampal formation (HF) is known from pathological and MRI studies to be severely atrophied in established Alzheimer's disease.
-
54/100
AD-MCI and AD-DEM patients showed increased p-tau217 and spectral slowing (higher theta, lower alpha).
-
Plasma was collected from 103 patients: 48 well-controlled (C, 31.3 % female) and 55 drug-resistant (DR, 50.9 % female).
-
The etiology of cerebrovascular pathology is heterogeneous.
-
Subjective cognitive decline (SCD) serves as an initial symptom of preclinical Alzheimer's disease (AD).
-
With advances in antiretroviral treatment, the population of older people living with HIV (PLWH) is increasing rapidly, leading to a rise in cognitive impairment related to both HIV and aging.
-
Differential FTP-PET signal patterns showed significant negative associations with domain-specific annual rates of decline.
-
All assessed BBM levels varied by over 10% by collection tube type.
-
Higher baseline WMH volume and higher GFAP were associated with a greater likelihood of diagnostic progression.
-
54/100
Plasma biomarkers were compared with densities of post-mortem-assessed amyloid plaques and neurofibrillary changes.
-
Sixty-nine HC, 13 preclinical AD, 38 AD-MCI, 44 AD-D, and 79 non-AD CI participants were included.
-
Intergrader agreements for overall 3 × 3 mm image quality and quantitative assessment of VD and FAZ ranged between 71% and 87% (52 images).
-
A subset of participants received cognitive testing and/or the Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III motor exam (off medication). 18F-PI-2620 uptake was low overall in Lewy body disease and correlated with β-amyloid PET in temporal lobe regions and precuneus.
-
Elevated CSF p-tau181 and cortical 18F-PI-2620 binding was characteristic for AD while normal CSF p-tau181 with elevated subcortical 18F-PI-2620 binding was characteristic for 4RTs. 18F-PI-2620-assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.
-
Glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) are putative non-amyloid biomarkers indicative of ongoing inflammatory and neurodegenerative disease processes.
-
54/100
Comorbid Alzheimer's disease (AD) neuropathology is common in Lewy body disease (LBD); however, AD comorbidity in the prodromal phase of LBD remains unclear.
-
This study investigates various pathological tau isoforms in the retina of individuals with early and advanced Alzheimer's disease (AD), exploring their connection with disease status.
-
N-terminal p-tau was increased in CJD versus SCD (p < 0.0001) and correlated with total tau (t-tau) in the presence of AD and PART co-pathology (rho = 0.758-0.952, p ≤ 001).
-
CSF exhibited increased levels of all SIMOA biomarkers in AD compared to Controls (AUCs: 0.71, 0.86, 0.92, and 0.94, respectively).
-
No asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive.
-
Neuropathological assessment was conducted on 1630 subjects, representing 5% of all the deceased that had been sent to the morgue of Uppsala University Hospital during a 15-year-long period.
-
Various plasma biomarkers for amyloid-β (Aβ) have shown high predictability of amyloid PET positivity.
-
Comparing the discordant CSF results of each patient with the cerebral amyloid-PET results, we found that in the group with Aβ1 - 42+ and p-tau-CSF values, the amyloid-PET was positive in 51.2% and negative in 48.8% of patients, while in the group with Aβ1 - 42-and p-Tau+ CSF values, the amyloid-PET was positive in 52.6% of patients and negative in 47.4% of them.
-
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
- Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness
- Alzheimer's blood-based biomarkers, incident dementia, and interactions with age, APOE status, and hormone therapy
- Cerebrospinal Fluid Biomarkers for Cerebral Amyloid Angiopathy Diagnosis
- Quantitative Water Permeability Mapping of Blood-Brain-Barrier Dysfunction in Aging
- Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease: from pathophysiology to individualized risk assessment
- Primary retinal tauopathy: A tauopathy with a distinct molecular pattern
- Disease-specific patterns of locus coeruleus cell loss
- Longitudinal brain structural changes in preclinical Alzheimer's disease
- Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia